GNPX stock forecast, quote, news & analysis
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes... Show more
Why Genprex (GNPX) Stock Is Down 25% in the Last 30 Days
Key Takeaways
- Genprex (GNPX) shares fell roughly 25% over the trailing 30 days, declining from about $2.75 to $2.07.
- The move extends a longer downtrend, with the stock down more than 50% over the trailing three-month period.
- Genprex is a pre-revenue, clinical-stage gene therapy company with recurring operating losses and a going-concern disclosure from its auditor.
- The lead oncology asset, REQORSA (quaratusugene ozeplasmid), remains in lung cancer clinical trials, with the Acclaim-3 interim analysis expected in the second half of 2026.
- The diabetes program, GPX-002, is still in preclinical development, keeping the pipeline tied to future data readouts.
- As a micro-cap biotech with limited liquidity, GNPX is prone to outsized price swings tied to financing and corporate developments.
- For additional detail on this ticker, explore its Price Targets, Earnings, and Forecast pages.
- You can also review automated trading strategies on Trending AI Robots.
Genprex (GNPX) Company Overview and Market Position
Genprex, Inc. is a clinical-stage gene therapy company headquartered in Austin, Texas, developing therapies for cancer and diabetes. The company generates no product revenue and funds its research primarily through equity financings. Its oncology platform uses a non-viral, lipid-based nanoparticle delivery system called ONCOPREX to deliver tumor-suppressor genes. The lead candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated in combination with approved cancer drugs in the Acclaim clinical trials for non-small cell lung cancer and small cell lung cancer, programs that carry FDA Fast Track designations and an Orphan Drug designation for the small cell lung cancer indication. Separately, the GPX-002 diabetes program uses an adeno-associated virus vector to deliver Pdx1 and MafA genes to the pancreas for Type 1 and Type 2 diabetes and remains in preclinical development. Investors follow GNPX for the binary potential of its lung cancer readouts, while acknowledging the early-stage, cash-intensive nature of the business.
Genprex (GNPX) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, GNPX declined approximately 24.7%, moving from a closing price of $2.75 to $2.07. The decline was not linear; the stock slipped through October and reached a low near $1.81 in late October before a brief rebound toward $2.24 that subsequently faded. The broader three-month picture is steeper, with shares falling more than 50% from roughly $4.27 to current levels. This sustained downtrend reflects persistent selling pressure rather than a single negative event, consistent with a thinly traded micro-cap equity facing ongoing funding needs and limited near-term catalysts.
What Drove GNPX Stock Price in the Last 30 Days
The 30-day decline occurred against a backdrop of recurring operational losses and financing pressure rather than one isolated headline. As a pre-revenue company, Genprex continues to consume cash to advance its clinical and preclinical programs, and its auditor has previously expressed doubt about the company's ability to continue as a going concern. Recent weeks also brought a series of corporate-governance and financing-related disclosures, which can weigh on investor sentiment when dilution risk is high. With a small float and relatively low average trading volume, even modest selling can produce disproportionate price moves, amplifying the downside. The late-October rebound attempt demonstrated the stock's high volatility, but the absence of new clinical data left the recovery unsustained.
What Drove GNPX Stock Performance Over the Last Quarter
The multi-month decline reflects the structural realities of a clinical-stage gene therapy company awaiting data. Over the quarter, shares slid from the mid-$4 range to below $2 as investors weighed the gap between the company's promising-but-unproven pipeline and its near-term capital requirements. Ongoing net losses, a going-concern disclosure, and the need for additional funding to reach key clinical milestones contributed to sustained downward pressure. Broader risk aversion toward pre-revenue biotechnology names also played a role. Meanwhile, the most consequential near-term catalyst, the Acclaim-3 Phase 2 interim analysis, has remained in the future, leaving the stock without a clear positive driver to offset the financing overhang.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's automated trading strategies. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots appear in this section. The featured robots vary by trading strategy, timeframe, and performance metrics, giving users a range of approaches to review rather than a single one-size-fits-all signal. For traders seeking to complement their own research with systematic, data-driven tools, exploring the Trending AI Robots section can provide additional perspective on current market activity.
GNPX Stock Forecast Drivers: What Investors Should Watch Next
The outlook for GNPX hinges on clinical execution and capital availability. The most important upcoming milestone is the Acclaim-3 Phase 2 interim analysis, which management has indicated is expected in the second half of 2026; enrollment progress in the Acclaim-1 and Acclaim-2 trials will also shape sentiment. On the diabetes side, progress toward IND-enabling studies and any regulatory feedback on GPX-002 could influence the stock. Equally critical are financing developments, including cash runway, potential dilution, and Nasdaq listing-compliance considerations. Quarterly earnings reports, beginning with the report expected in mid-November, will provide updates on spending and trial timelines. As always with early-stage biotechs, binary clinical outcomes and funding risks remain the dominant variables for investors to monitor.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for GNPX turns positive, indicating new upward trend
GNPX saw its Momentum Indicator move above the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 71 similar instances where the indicator turned positive. In 60 of the 71 cases, the stock moved higher in the following days. The odds of a move higher are at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where GNPX's RSI Oscillator exited the oversold zone, 36 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
Following a +11.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where GNPX advanced for three days, in 150 of 197 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
GNPX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 32 cases where GNPX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNPX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for GNPX entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.115) is normal, around the industry mean (3.498). P/E Ratio (0.060) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. GNPX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GNPX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of molecular therapies for cancer treatment
Industry Biotechnology